[Federal Register Volume 68, Number 134 (Monday, July 14, 2003)]
[Notices]
[Pages 41661-41662]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-17716]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importation of Controlled Substances; Notice of Application

    Pursuant to section 1008 of the Controlled Substances Import and 
Export Act (21 U.S.C. 958(1)), the Attorney General shall, prior to 
issuing a registration under this section to a bulk manufacturer of a 
controlled substance in Schedule I or II and prior to issuing a 
registration under section 1002(a) authorizing the importation of such 
a substance, provide manufacturers holding registrations for the bulk 
manufacture of the substance an opportunity for a hearing.
    Therefore, in accordance with section 1301.34 of Title 21, Code of 
Federal Regulations (CFR), notice is hereby given that on March 20, 
2003, Cambrex North Brunswick, Inc., Technology

[[Page 41662]]

Centre of New Jersey, 661 Highway One, North Brunwswick, New Jersey 
08902, made application by renewal to the drug Enforcement 
Administration to be registered as an importer of Phenylacetone (8501), 
a basic class of controlled substance listed in Schedule II.
    The firm plans to import the listed controlled substances to 
manufacture amphetamine.
    Any manufacturer holding, or applying for, registration as a bulk 
manufacturer of this basic class of controlled substances may file 
written comments on or objections to the application described above 
and may, at the same time, file a written request for a hearing on such 
application in accordance with 21 CFR 1301.43 in such from as 
prescribed by 21 CFR 1316.47.
    Any such comments, objections, or requests for a hearing may be 
addressed, in quintuplicate, to the Deputy Assistant Administrator, 
Office of Diversion Control, Drug Enforcement Administration, United 
States Department of Justice, Washington, DC 20537, Attention: Federal 
Register Representative, Office of Chief Counsel (CCD) and must be 
filed no later than September 13, 2003.
    This procedure is to be conducted simultaneously with an 
independent of the procedures described in 21 CFR 1301.34(b), (c), (d), 
(e), and (f). As noted in a previous notice at 40 FR 43745-46 
(September 23, 1975), all applicants for registration to import a basic 
class of any controlled substance in Schedule I or II are and will 
continue to be required to demonstrate to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration that the requirements for such registration pursuant to 
21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1311.42(a), (b), (c), 
(d), (e) and (f) are satisfied.

    Dated: June 25, 2003.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 03-17716 Filed 7-11-03; 8:45 am]
BILLING CODE 4410-09-M